Shah, Mithun Vinod http://orcid.org/0000-0002-5359-336X
Mangaonkar, Abhishek A. http://orcid.org/0000-0003-2458-9887
Begna, Kebede H.
Alkhateeb, Hassan B. http://orcid.org/0000-0002-3609-8404
Greipp, Patricia
Nanaa, Ahmad http://orcid.org/0000-0001-5247-5065
Elliott, Michelle A.
Hogan, William J. http://orcid.org/0000-0002-5841-4105
Litzow, Mark R. http://orcid.org/0000-0002-9816-6302
McCullough, Kristen http://orcid.org/0000-0003-4252-2619
Tefferi, Ayalew http://orcid.org/0000-0003-4605-3821
Gangat, Naseema http://orcid.org/0000-0002-9104-6172
Patnaik, Mrinal M. http://orcid.org/0000-0001-6998-662X
Al-Kali, Aref http://orcid.org/0000-0002-0824-3715
He, Rong http://orcid.org/0000-0001-6116-8163
Chen, Dong
Funding for this research was provided by:
Leukemia Research Foundation
Article History
Received: 25 March 2022
Revised: 21 June 2022
Accepted: 28 June 2022
First Online: 8 July 2022
Competing interests
: Patnaik—Membership on an entity’s Board of Directors or advisory committees (Stemline Therapeutics) and Research funding (Kura Oncology). Al-Kali—Research funding (Novartis), and Research support to institution (Astex). Litzow—Research funding (AbbVie, Astellas, Amgen, Actinium, Pluristem); Advisory board (Jaz, Omeros); Data monitoring committee (BioSight). All other authors disclose no conflicts.